Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
Lepodisiran reduced mean serum concentrations of lipoprotein(a) from 60 to 180 days after administration. (Funded by Eli Lilly; ALPACA ClinicalTrials.gov number, NCT05565742.).
Authors
- Xi Shen (ORCID: https://orcid.org/0000-0001-7568-7335)
- Steven E. Nissen (ORCID: https://orcid.org/0000-0002-7231-6464)
- Axel Haupt (ORCID: https://orcid.org/0000-0003-4502-0470)
- Ann Marie Návar (ORCID: https://orcid.org/0000-0002-6197-9860)
- Laura Michael
- Stephen James Nicholls (ORCID: https://orcid.org/0000-0002-9668-4368)
- John H. Krege (ORCID: https://orcid.org/0000-0003-3914-0951)
- Wei Ni (ORCID: https://orcid.org/0000-0003-3494-9217)
- Qiuqing Wang
- Kathy Wolski
Institutions
- Cleveland Clinic (US)
- Eli Lilly (United States) (US)
- Center for Clinical Research (United States) (US)
- Monash University (AU)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-03-30
- DOI
- https://doi.org/10.1056/nejmoa2415818
- Citations
- 77
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 154.50
Funders
- Eli Lilly and Company